Patent application number | Description | Published |
20090053198 | Cytokine Induction of Selectin Ligands on Cells - Methods and compositions for treating cells with cytokines are provided herein. | 02-26-2009 |
20090239296 | Compositions and Methods for Modifying Cell Surface Glycans - Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein. | 09-24-2009 |
20110177040 | Cytokine Induction Of Selectin Ligands On Cells - Methods and compositions for treating cells with cytokines are provided herein. | 07-21-2011 |
20110189139 | Hematopoietic Cell E-Selectin/L-Selectin Ligand Glycosylated CD44 Polypeptide - The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal. | 08-04-2011 |
20120107281 | COMPOSITIONS AND METHODS FOR MODIFYING CELL SURFACE GLYCANS - Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein. | 05-03-2012 |
20120107924 | COMPOSITIONS AND METHODS FOR MODIFYING CELL SURFACE GLYCANS - Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein. | 05-03-2012 |
20120321601 | Increased In Vivo Circulation Time of Platelets After Storage With A Sialidase Inhibitor - The present invention relates to methods, compositions and kits for increasing the in vivo circulation time of isolated platelets by storing the platelets with one or more sialidase inhibitors. | 12-20-2012 |
20130058959 | HEMATOPOIETIC CELL SELECTIN LIGAND POLYPEPTIDES AND METHODS OF USE THEREOF - The invention feature methods and compositions for treating inflammatory disorders, hematopoietic disorders and non-hematopoietic disorders (e.g., non-hematopoietic cancers) and for isolating cells (e.g., stem cells) in a mammal. | 03-07-2013 |
20130059333 | HEMATOPOIETIC CELL SELECTIN LIGAND POLYPEPTIDES AND METHODS OF USE THEREOF - The invention feature methods and compositions for treating inflammatory disorders, hematopoietic disorders and non-hematopoietic disorders (e.g., non-hematopoietic cancers) and for isolating cells (e.g., stem cells) in a mammal. | 03-07-2013 |
20130089927 | Hematopoietic Cell E-Selectin/L-Selectin Ligand Polypeptides and Methods of Use Thereof - The invention features methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal. | 04-11-2013 |
20130224217 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION - The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO activity. The inhibitors may be administered in conjunction with G-CSF therapy. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′) | 08-29-2013 |
20140099629 | Platelet Additive Solution Having a beta-Galactosidase Inhibitor - The present invention relates to a platelet additive solution (PAS) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof. | 04-10-2014 |
20140170120 | CYTOKINE INDUCTION OF SELECTIN LIGANDS ON CELLS - Methods and compositions for treating cells with cytokines are provided herein. | 06-19-2014 |
20140199316 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION - The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO activity. The inhibitors may be administered in conjunction with G-CSF therapy. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′) | 07-17-2014 |